Skip to content

Talphera, Inc. TLPH Payments to Acquire Short-Term Investments

Payments to Acquire Short-Term Investments at other companies

Syndax Pharmaceuticals logo
Syndax PharmaceuticalsSNDX

Other financials

Income statement

See full
Revenue--100%
Gross profit-$1.9M-52.7%
Operating income-$3.9M-35.4%
Net income-$2.6M+1.4%
EPS (diluted)-$0.10+37.5%

Balance sheet

See full
Cash & equivalents$3.8M-29.0%
Total debt$3.4M-79.7%
Total equity$18.5M+230%
Total assets$30.2M+101%

Cash flow

See full
Operating cash flow-$3.4M+2.0%
CapEx-
Free cash flow-$2.3M+42.9%

Valuation

See full
Market cap$53.46M+516%
P/S53,456.6×+53,135×

Profitability

See full
Gross margin-127.7%-136pp
Operating margin-1,451,600%-1,507,145pp
Net margin-1,425,300%-1,471,200pp
FCF margin-5,116.7%-6,779pp

Returns & leverage

See full
Return on equity-118.4%+15.4pp
Debt / equity0.2×
Current ratio5.3×+2.2×

Where this comes from

Reported directly by Talphera, Inc. in its filing.

Tagged under the XBRL concept us-gaap:PaymentsToAcquireShortTermInvestments.

The official record: Talphera, Inc.’s 10-Q, filed May 13, 2026, on SEC EDGAR. View the filing →

Ask your AI about Talphera, Inc.'s payments to acquire short-term investments.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is Talphera, Inc.'s payments to acquire short-term investments?
Talphera, Inc. (TLPH) reported payments to acquire short-term investments of $17.24M in Q1 2026.
What is the long-term trend for Talphera, Inc.'s payments to acquire short-term investments?
Over 2 years (2021 to 2023), Talphera, Inc.'s payments to acquire short-term investments has grown at a -77.2% compound annual growth rate (CAGR), from $70.46M to $3.65M.